Bangweixin^® Rabeprazole Sodium Enteric-Coated Tablets are developed based on the concept of Quality by Design (QbD) and using systematic, scientific, and rigorous experimental design methods. This ensures the safety, efficacy, and controllability of the drug quality. It is the second proton pump inhibitor in Qingfeng’s digestive field after Bankaxin^® Esomeprazole Magnesium Enteric-Coated Tablets. This product was approved for market in August 2023 and is the most potent proton pump inhibitor against Helicobacter pylori. It is mainly used for gastric ulcers, duodenal ulcers, anastomotic ulcers, reflux esophagitis, and Zollinger-Ellison syndrome. It is also used as an adjunct in the eradication of Helicobacter pylori in gastric or duodenal ulcer patients. Bangweixin^® Rabeprazole Sodium Enteric-Coated Tablets have a wide range of applications and have been included in the national medical insurance Category B list. It is currently one of the most commonly used oral PPIs in China.